Eyeing Chinese IVD Market, OriGene Buys BioCheck | GenomeWeb

OriGene Technologies said this week that it has acquired Foster City, Calif.-based immunoassay firm BioCheck.

The acquisition expands Origene's in vitro diagnostic portfolio and capabilities for future product development, the company said. In particular, the purchase provides OriGene with IVD products for the Chinese clinical market, currently a major area of focus for the company.

According to OriGene, the Chinese IVD market is among the fastest growing in the world and is predicted to be the second largest globally by 2017.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.